Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in south Asian population

Clinical and Translational Gastroenterology

Volumn 5, Issue , 2014, Pages

  Tan, Sheryl S L ^a   Khin, Lay W ^a   Wong, Lingkai ^b   Yan, Benedict ^c,d   Ong, Chee W ^e   Datta, Arpita ^a   Salto Tellez, Manuel ^c,e   Lam, Yulin ^b   Yap, Celestial T ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUND 5C; FLUOROURACIL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SMALL INTERFERING RNA; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE SILENCING; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SOUTH ASIAN; SURVIVAL PREDICTION; SURVIVAL TIME;

EID: 84893917906     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2013.21     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Johnston P, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 2001; 12: 639-646.
3. Knijn N, Tol J, Punt CJ. Current issues in the targeted therapy of advanced colorectal cancer. Discov Med 2010; 9: 328-336.
4. Kolesnick R, Hannun Y. Ceramide and apoptosis. Trends Biochem Sci 1999; 24: 224-225; author reply 227.
5. Cuvillier O, Pirianov G, Kleuser B et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381: 800-803.
6. Cuvillier O. Sphingosine kinase-1 - a potential therapeutic target in cancer. Anticancer Drugs 2007; 18: 105-110.
7. Shida D, Takabe K, Kapitonov D et al. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008; 9: 662-673.
8. Kawamori T, Osta W, Johnson K et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006; 20: 386-388.
9. Kawamori T, Kaneshiro T, Okumura M et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009; 23: 405-414.
10. Ruckhäberle E, Rody A, Engels K et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008; 112: 41-52.
11. Li W, Yu C, Xia J et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009; 15: 1393-1399.
12. Ahn E, Schroeder J. Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp Biol Med (Maywood) 2002; 227: 345-353.
13. Selzner M, Bielawska A, Morse M et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61: 1233-1240.
14. Oskouian B, Saba J. Sphingosine-1-phosphate metabolism and intestinal tumorigenesis: lipid signaling strikes again. Cell Cycle 2007; 6: 522-527.
15. Greenspon J, Li R, Xiao L et al. Sphingosine-1-phosphate protects intestinal epithelial cells from apoptosis through the Akt signaling pathway. Dig Dis Sci 2009; 54: 499-510.
16. Oskouian B, Sooriyakumaran P, Borowsky AD et al. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc Natl Acad Sci USA 2006; 103: 17384-17389.
17. Kohno M, Momoi M, Oo M et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006; 26: 7211-7223.
18. Salto-Tellez M, Nga ME, Han HC et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer 2007; 96: 776-782.
19. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999; 20: 145-157.
20. Wong L, Tan SS, Lam Y et al. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem 2009; 52: 3618-3626.
21. Billich A, Ettmayer P. Fluorescence-based assay of sphingosine kinases. Anal Biochem 2004; 326: 114-119.
22. Nemoto S, Nakamura M, Osawa Y et al. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 2009; 284: 10422-10432.
23. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44.
24. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
25. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997; 16: 901-910.
26. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170: 244-256.
27. Rosa R, Marciano R, Malapelle U et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res 2013; 19: 138-147.
28. Pchejetski D, Doumerc N, Golzio M et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008; 7: 1836-1845.
29. Sukocheva O, Wadham C, Holmes A et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 2006; 173: 301-310.
30. Vadas M, Xia P, McCaughan G et al. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta 2008; 1781: 442-447.
31. Miller AV, Alvarez SE, Spiegel S et al. Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol Cell Biol 2008; 28: 4142-4151.
32. Shida D, Kitayama J, Yamaguchi H et al. Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun 2005; 327: 907-914.
33. Limaye V, Li X, Hahn C et al. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 2005; 105: 3169-3177.
34. Xia P, Wang L, Gamble JR et al. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 1999; 274: 34499-34505.
35. Le Scolan E, Pchejetski D, Banno Y et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005; 106: 1808-1816.
36. Radeff-Huang J, Seasholtz T, Chang J et al. Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and cyclin D expression. J Biol Chem 2007; 282: 863-870.
37. Kapitonov D, Allegood J, Mitchell C et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009; 69: 6915-6923.
38. Dayon A, Brizuela L, Martin C et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One 2009; 4: e8048.
39. Pyne N, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.